{"entity":{"id":"nct05994131","kind":"trial","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","aka":[],"tldr":"A phase 1/2 trial of IN10018 and Furmonertinib in non-small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.","summary":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC is a phase 1/2 interventional study registered as NCT05994131 by InxMed (Shanghai) Co., Ltd., with 110 participants planned, started 2023-07-13 and due to reach its primary completion in 2026-07-31. Interventions recorded: IN10018 and Furmonertinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05994131","url":"https://clinicaltrials.gov/study/NCT05994131"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["in10018","furmonertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05994131","phase":"1/2","setting":"A Multicenter, Open-label, Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Anti-tumor Efficacy of IN10018 Combined With Third-generation EGFR-TKI in Patients With Advanced EGFR Mutation-positive NSCLC","sponsor":"InxMed (Shanghai) Co., Ltd.","enrolled":110,"outcomes":[]},"route":"/trials/nct05994131/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}]}}